{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade 3- Weight loss"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade 3- Mucositis oral"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade 3- Hypertension"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade 3- wrist pain"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade 3-Dysphagia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade 3- Lymphedema"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade 3- Odynophagia"}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"description":"To characterize the Grade 3-4 chronic toxicities of adjuvant durvalumab with radiotherapy in intermediate-risk Head and Neck Squamous Cell Carcinoma patients. Toxicity was assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE v4.03).","groups":[{"description":"Durvalumab in combination with intensity modulated radiotherapy (IMRT) treatments\n\nDurvalumab: Durvalumab 1500mg IV every 3 weeks for 6 cycles\n\nIntensity Modulated Radiotherapy Treatments: Total dose will be 60 Gray (Gy) at 2Gy per fractions for 30 fractions delivered Monday through Friday for 6 weeks","id":"OG000","title":"Open-label, Single-arm"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The type of Grade 3 Adverse Events observed in 5 subjects were included.","reportingStatus":"POSTED","timeFrame":"12 weeks","title":"Chronic Toxicities of Adjuvant Durvalumab With Radiotherapy","type":"SECONDARY","unitOfMeasure":"Participants"}